Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy
Conditions
Keywords
Kidney transplantation, Immunosuppression, IFN-γ
Brief summary
The main objective of the study is to demonstrate the utility and safety of the IFN-γ (Interferon Gamma) ELISPOT (Enzyme-linked immunosorbent spot) marker for the stratification of kidney transplant recipients into low and high IS (Immunosuppression) regimens. The enrichment study will test non-inferiority of low IS regimen compared to high IS regimen, assuming 10% of BPAR at 6-months in the control group, and allowing a non-inferiority limit of maximum 10%.
Interventions
DRUGTacrolimus (for Group B)
Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
DRUGMMF (mycophenolate mofetil) (for Group B)
MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose. Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax. From day 8 on, patients will not receive MMF.
DRUG6-methyl prednisolone (Steroids) (for Group B)
At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred). Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed.
DRUGTacrolimus (for Group A)
The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study. Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.
DRUGMycofenolate mofetil (MMF) (for Group A)
Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose. Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™). The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation.
DRUG6-methyl prednisolone (Steroids) (for Group A)
At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A). Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day.
Sponsors
Prof. Dr. Petra Reinke
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women, age ≥18 years. 2. Subject must be a recipient of a first renal transplant from a deceased or living donor. 3. Subject must have a current documented PRA (Panel of reactive antibodies) \<20% and no detectable anti-class I and II HLA (human leukocyte Antigens) antibodies by solid phase assay (Luminex®). 4. Subject is willing to provide signed written informed consent. 5. Women of Childbearing Potential (WOCBP) must be using a highly effective method of contraception (Pearl-Index \< 1) to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL\]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG (Human chorionic gonadotropin)) within 72 hours prior to the start of clinical trial.
Exclusion criteria
1. Subjects undergoing renal transplant with a current documented PRA \>20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®). 2. CDC (complement dependent cytotoxicity) positive cross match. 3. Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes. 4. Cold ischemia time (CIT) higher than 24h. 5. Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT. 6. Patients previously treated with daclizumab or basiliximab. 7. Subjects with underlying renal disease of: * Primary focal segmental glomerulosclerosis. * Type I or II membranoproliferative glomerulonephritis * Atypical Haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura syndrome. 8. Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive PCR (polymerase chain reaction result) at the moment of transplant. 9. Subjects with known human immunodeficiency virus (HIV) infection. 10. Patients with active systemic infection that requires the continued use of antibiotics. 11. Patients with neoplasia except localized skin cancer receiving appropriate treatment. 12. Patients with severe anemia (hemoglobin \< 6g/dl), leucopenia (WBC (White blood cells) \<2500/mm3), thrombocytopenia (platelets \<80.000/mm3). 13. Hemodynamically instable patients even if their hemoglobin level counts \> 6 g/dl. 14. Patients with intestinal pathology or severe diarrhoea that can hinder absorption according to medical criteria. 15. Subjects with a known hypersensibility to any of the drugs used in this protocol. 16. Subjects who have used any investigational drug within 30 days prior to enrolment in this clinical trial. 17. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment. 18. Subjects who are legally detained in an official institution
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| assessment of anti-donor T-cell alloresponses using the IFN-γ ELISPOT test | 6 months | Patients with a positive anti-donor IFN-γ ELISPOT assay result (\>25 spots/300.000 PBMC (peripheral blood mononuclear cells )) will be ruled out of the study and patients with negative anti-donor IFN-γ ELISPOT test (\<25 spots/300.000 PBMC) will be randomized in 2 different groups (1:1). The main objective of the study is to demonstrate the utility and safety of the IFN-γ ELISPOT marker for the stratification of kidney transplant recipients into low and high IS regimens. |
Secondary
| Measure | Time frame |
|---|---|
| Differences across Treatment arms in Biopsy proven acute rejection rate (BPAR rate) | after 6 and 12 months |
| Differences across Treatment arms in subclinical rejection rate using renal allograft biopsy | after 3 and 12 months |
| Differences across Treatment arms in Prevalence of death, and graft loss | after 6 and 12 months |
| Differences across Treatment arms in Prevalence of metabolic and cardiovascular co-morbidity (new onset diabetes mellitus (NODAT, dyslipidaemias, hypertension) | 12 months |
| Differences across Treatment arms in Prevalence of subjects that remain MMF and steroid-free | after 6 and 12 months |
| Differences across Treatment arms in Prevalence of Acute and chronic histologic lesions assessed by the Bannf'11 score in protocol biopsies | after 3 and 12 months |
| Differences across Treatment arms in Prevalence of patients that remain on Therapy | after 12 months |
| Differences across Treatment arms in Distribution of patients in distinct chronic kidney diseases (CKD) stages | after 12 months |
| Differences across Treatment arms in treatment cost (cost/benefit) | after 1,3,6,12 and 24 months |
| Differences across Treatment arms in eGFR (estimated glomerular Filtration rate) (ml/min) | after 3, 6 and 12 months |
| Differences across Treatment arms in assessment of anti-donor and anti-HLA antibodies by Solid phase assays (Luminex®) and B-cell ELISPOT | at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR |
| Differences across Treatment arms in different viral load (CMV, EBV, BKV) | at months 1, 2, 3, 6 and 12 after transplantation |
| Differences across Treatment arms in study of virus-specific T-cell responses (ELISPOT) | at at pre-transplantation, 3, 6 and 12 after transplantation |
| Differences across Treatment arms in prevalence of transcriptional genes by RT-PCR in PBMC (peripheral blood mononuclear cells ) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR |
| Differences across Treatment arms in flow cytometry assessment of peripheral blood mononuclear cells (PBMC) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of BPAR |
| Differences across Treatment arms in Quantitative analyses of urinary IP-10 (Interferon Gamma induced Protein) | at 4 weeks and at 3, 6 and 12 month after transplantation as well as at time of BPAR |
| Differences across Treatment arms in Assessment of protocol biopsies | at month 3 and 12 after transplantation |
| Differences across Treatment arms in MicroRNA assessment in sera and urine | at pre-transplantation and months 1, 3, 6 and 12 after transplantation |
| Differences across Treatment arms in evaluation of FOXP3 (Forkhead box P3) methylation degree at the TSDR (Treg-specific demethylated Region) | at pre-transplantation and months 1, 3, 6 and 12 after transplantation as well as at time of rejection |
| Differences across Treatment arms in development of a Panel reactive T (PRT)-cell response platform to evaluate general anti-HLA T-cell Responses using ELISPOT | at pre-transplantation, 3, 6 and 12 months after transplantation as well as at time of BPAR |
Countries
Czechia, France, Germany, Netherlands, Spain, United Kingdom
Outcome results
None listed